New Insights into Anti-rheumatic Drugs

by Colleen Fleiss on  May 12, 2018 at 11:18 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Stopping tumor necrosis factor inhibitors in patients with stable low disease activity, on average, was associated with a cost saving of €7,133, a loss of 0.022 quality-adjusted life years, and an increase of 0.41 arthritis flares per patient per year, reveals study published in Arthritis & Rheumatology.
New Insights into Anti-rheumatic Drugs
New Insights into Anti-rheumatic Drugs

In the study, "The subpopulation of patients receiving biological disease modifying anti-rheumatic drugs including tumor necrosis factor inhibitors... has increased over time and accounted for up to 20% of the population of rheumatoid arthritis patients in various Western healthcare systems," the authors wrote.

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints and the surrounding tissues. It is an autoimmune disease.

Source: Eurekalert
Advertisement

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Drugs Banned in India 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...